enGene Raises $149.5M for EG-70 Bladder Cancer Trial Amid CFO Appointment and Stake Surge

EnGene Holdings Inc.

ENGENE HOLDINGS INC (NASDAQ: ENGN) is a clinical-stage biotechnology company headquartered in Boston, Massachusetts. As of November 28, 2025, the stock closed at $8.36, reflecting a 1.33 percent increase on volume of 212,531 shares. The company’s market capitalization is approximately $438 million, with a one-year target estimate set at $23.70.

Corporate Structure and Leadership

Founded in 1999, enGene employs between 11 and 50 people across its Boston and Montreal sites. On November 29, 2023, the company appointed Ryan Daws as Chief Financial Officer and Head of Business Development. Mr. Daws has nearly 25 years of experience in pharmaceutical operations, healthcare investment banking, and deal-making, having held senior finance roles at Obsidian Therapeutics, Robert W. Baird & Co., and Concert Pharmaceuticals.

Biotechnology by Louis Reed

Developments and News

On November 14, 2025, enGene filed an SEC Form 8-K detailing leadership appointments (Item 1.01), entry into a material definitive agreement (Item 7.01), and financial statements (Item 9.01). On November 18, 2025, two Schedule 13G filings disclosed that Deep Track Capital, LP and its affiliates beneficially own 4,317,332 shares, representing 6.69 percent of outstanding stock, while Perceptive Advisors LLC and associated entities hold 6,770,605 shares, or 9.99 percent. A LinkedIn announcement indicated the completion of a public offering that raised approximately $149.5 million in gross proceeds, including the full exercise of underwriters’ option to purchase additional shares. These proceeds are allocated to advance EG-70, the lead program in a pivotal Phase 2 study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

Financial and Strategic Analysis

Over the trailing twelve months, enGene reported a net loss of $94.7 million and negative diluted EPS of $1.90. Total cash available as of the most recent quarter was $201.9 million, with a debt-to-equity ratio of 15.6 percent. The company currently does not have a PE ratio and has generated levered free cash flow of –$60.1 million. As of November 13, 2025, price/book was recorded at 2.20, with a beta of –0.26, indicating a low correlation with broader market movements. Share turnover remains elevated; the average daily volume reported on Yahoo Finance was approximately 1.1 million shares compared to an intraday tally of 1.7 million on November 13, 2025.

Strategically, enGene utilizes its proprietary Dually Derivatized Oligochitosan (DDX) platform to deliver DNA and RNA payloads to mucosal tissues. The company expects to release interim data from the EG-70 pivotal cohort in mid-2024, which will support a planned biologics license application submission in the second half of 2026.

Market Position and Industry Context

Operating in the biotechnology research sector, enGene focuses on non-viral gene-based immunotherapy with an initial concentration on NMIBC. As a clinical-stage company, it competes with entities developing intravesical therapies and emerging gene-delivery platforms. Institutional investors, including Deep Track and Perceptive Advisors, hold nearly 17 percent of the equity, indicating their involvement in the company's strategic direction.

tl;dr

Ryan Daws was appointed as CFO on November 29, 2023. SEC filings on November 14 and 18, 2025, provided details on leadership agreements and significant ownership stakes by Deep Track Capital (6.69 percent) and Perceptive Advisors (9.99 percent). A public offering raised approximately $149.5 million to fund the EG-70 Phase 2 pivotal trial for BCG-unresponsive NMIBC, with interim data expected in mid-2024 and a BLA submission targeted for the second half of 2026. Earnings reports are scheduled to occur between September 10 and September 25, 2025, with a one-year analyst price target of $23.70.